Skip to Content

Medtronic PLC MDT

Morningstar Rating
$79.76 −0.23 (0.29%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

Company Report

Medtronic Earnings: Recently Approved New Products Should Support Growth Into Fiscal 2025

Medtronic posted strong fiscal 2024 second-quarter results that put it on track to meet our full-year expectations, and we’re leaving our $112 fair value estimate unchanged. We think this quarter demonstrated more progress on the firm's larger objective of matching market growth. Organic revenue growth of 5% was fueled by strength in stent grafts for abdominal aortic aneurysm, the digital Aible system for spine procedures, and GI Genius, which incorporates artificial intelligence to better detect polyps during colonoscopy. Importantly, Medtronic recently obtained regulatory approval on several emerging technologies that we see as key growth drivers. These innovative new products reinforce the intangible assets that support Medtronic’s wide economic moat.

Price vs Fair Value

MDT is trading at a 29% discount.
Price
$79.76
Fair Value
$523.00
Uncertainty
Medium
1-Star Price
$363.30
5-Star Price
$59.60
Economic Moat
Fhy
Capital Allocation
Wlmryldcw

Bulls Say, Bears Say

Bulls

Medtronic has historically held roughly 50% share in its core heart devices. It's also the market leader in spinal products, insulin pumps, and neuromodulators for chronic pain.

Bears

As smaller firms introduce new insulin pump technology, Medtronic may face a stiffer fight to maintain its leadership in this arena.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$79.99
Day Range
$79.4180.23
52-Week Range
$68.8492.02
Bid/Ask
$79.07 / $81.20
Market Cap
$106.09 Bil
Volume/Avg
7 / 6.8 Mil

Key Statistics

Price/Earnings (Normalized)
14.74
Price/Sales
3.33
Dividend Yield
3.44%
Dividend Yield (Forward)
3.46%
Total Yield
3.66%

Company Profile

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Value
Total Number of Employees
95,000

Competitors

Valuation

Metric
MDT
BSX
JNJ
Price/Earnings (Normalized)
14.7428.0915.14
Price/Book Value
2.064.255.37
Price/Sales
3.335.794.75
Price/Cash Flow
14.3529.1718.67
Price/Earnings
MDT
BSX
JNJ

Financial Strength

Metric
MDT
BSX
JNJ
Quick Ratio
1.420.670.86
Current Ratio
2.291.421.21
Interest Coverage
8.968.0720.16
Quick Ratio
MDT
BSX
JNJ

Profitability

Metric
MDT
BSX
JNJ
Return on Assets (Normalized)
7.71%8.56%14.22%
Return on Equity (Normalized)
13.75%15.65%35.35%
Return on Invested Capital (Normalized)
9.80%10.89%22.60%
Return on Assets
MDT
BSX
JNJ

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ABT
Abbott LaboratoriesDhbdyq$182.6 Bil
SYK
Stryker CorpYwsv$110.5 Bil
BSX
Boston Scientific CorpMbpsj$80.2 Bil
DXCM
DexCom IncDtvzx$45.1 Bil
EW
Edwards Lifesciences CorpWhjsqmg$42.0 Bil
ZBH
Zimmer Biomet Holdings IncSvfl$24.4 Bil
PHG
Koninklijke Philips NV ADRGfygyn$18.9 Bil
ALGN
Align Technology IncKpjlkl$16.8 Bil
PODD
Insulet CorpTnbdbq$13.5 Bil